Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822586 · ClinicalTrials.gov registry record · Phase 1
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02822586: Completed Phase 1 study, sponsored by Virginia Commonwealth University.
NCT02822586 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02822586, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.
Primary Outcome
Selected cutaneous adverse events (AEs) that occurred during treatment or during the 3 months following initiation of study treatment and that are characterized and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0) including ≥ grade 3 AEs and selected grade 2 AEs
Interventions
- DRUG Brentuximab vedotin
- RADIATION TSEB Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-12-19 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 1 |
What the finished NCT02822586 record still lists
NCT02822586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Brentuximab vedotin is the first listed.
NCT02822586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02822586 about?
NCT02822586 is a clinical study titled "TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome". The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.
What is the current status of trial NCT02822586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-12-19. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT02822586?
The interventions under investigation include: Brentuximab vedotin (DRUG), TSEB Therapy (RADIATION).
Who is sponsoring clinical trial NCT02822586?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02822586's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI